The 24 best-selling prescription drugs in the world in 2019

The list was compiled by Yongjiang Taro, a senior pharmaceutical industry analyst in Japan who has ranked multinational pharmaceutical companies and global drug sales for more than 20 years, and annually aggregates the annual sales of heavy-duty prescription drugs from January to December of the past year, and if a drug is promoted jointly by multiple companies, the cumulative sales calculation can be seen in comparison with the past list, which can reveal changes in the market for these heavyweight brandsis the world's top 24 prescription drugs for 2019, each with sales of more than $4 billion in the past year:total sales grew from $139 billion in 2013 to $175 billion last year, compared with the 2013 listThe U.Sdollar, which has been the "drug king" topping the list, remained close to $20 billion in sales in 2019 despite a drop in revenue from the impact of biosimilars in the European market, and similar autoimmune agents Enley and Class, which are also on the listare not only sourcin, roche products, excluding Anvitin, were hit by a decline in sales in 2013the number of more than $4 billion increased by only two in 2019, but the number of varieties over $8 billion increased from five in 2013 to eightbiologics continue to take a larger share of the market, increasing from 10 to 14 compared to the 2013 list, so to speak, today's multinational pharmaceutical companies will be largely constrained by sales growth without biologicsthe 24 best-selling drugs in the world in 2019, the highest number of anti-tumor drugs, reached nine, followed by autoimmune drugs, four when Starnon is included, followed by anti-HIV drugs and multiple sclerosis drugs, with two eachin the 2013 list, there are 11 slow-onset drugs that sell more than $4 billion a year, such as the buck drug Novartis, GSK's Schulydy, Bollinger Ingerheim's Silihua, and the fat-lowering drug AstraZeneca' in 2019The under-diabetes drugs Genovy and insulin and sharp, even with the anticoagulant al-Elto, Bereto, and the new diabetes drug Easy, a total of only 5, and the Genovi market is still shrinking, in the list of these slow-disease drugs, can still maintain growth is easy to reach, the market for slow-disease heavy drugs have not much expectation.